Literature DB >> 9119990

Hyperexpression of mitogen-activated protein kinase in human breast cancer.

V S Sivaraman1, H Wang, G J Nuovo, C C Malbon.   

Abstract

Mitogen-activated protein (MAP) kinases act as transducers of extracellular signaling via tyrosine kinase-growth factor receptors and G-protein-linked receptors to elements regulating transcription. The activity, abundance, and localization of MAP kinase was investigated in normal and malignant neoplasia of the breast. In carcinoma of the breast, MAP kinase was heavily phosphorylated on tyrosyl residues and its activity elevated 5-10-fold over benign conditions, such as fibroadenoma and fibrocystic disease. By in situ reverse transcription-polymerase chain reaction, hyperexpression of MAP kinase mRNA can be localized to malignant, epithelial cells. Metastatic cells within involved lymph nodes of patients with breast cancer also display hyperexpression of MAP kinase. In spite of persistent activation via phosphorylation, MAP kinase expression is upregulated 5-20-fold and this hyperexpression may be a critical element to initiation as well as the metastatic potential of various forms of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119990      PMCID: PMC507966          DOI: 10.1172/JCI119309

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

Review 1.  How MAP kinases are regulated.

Authors:  M H Cobb; E J Goldsmith
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

Review 2.  Signal transduction via the MAP kinases: proceed at your own RSK.

Authors:  J Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

3.  Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.

Authors:  A Brunet; G Pagès; J Pouysségur
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

4.  Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.

Authors:  P W Janes; R J Daly; A deFazio; R L Sutherland
Journal:  Oncogene       Date:  1994-12       Impact factor: 9.867

5.  In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues.

Authors:  G J Nuovo; A Forde; P MacConnell; R Fahrenwald
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

6.  Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.

Authors:  G J Nuovo; P B MacConnell; A Simsir; F Valea; D L French
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

7.  Raf-1 protein expression in human breast cancer cells.

Authors:  L S Callans; H Naama; M Khandelwal; R Plotkin; L Jardines
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

8.  MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts.

Authors:  S K Gupta; C Gallego; G L Johnson; L E Heasley
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

Review 9.  Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer.

Authors:  R B Dickson; D S Salomon; M E Lippman
Journal:  Cancer Treat Res       Date:  1992

10.  Cancer statistics, 1995.

Authors:  P A Wingo; T Tong; S Bolden
Journal:  CA Cancer J Clin       Date:  1995 Jan-Feb       Impact factor: 508.702

View more
  104 in total

1.  Active erk regulates microtubule stability in H-ras-transformed cells.

Authors:  R E Harrison; E A Turley
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

2.  ERK2 enters the nucleus by a carrier-independent mechanism.

Authors:  Angelique W Whitehurst; Julie L Wilsbacher; Youngjai You; Kate Luby-Phelps; Mary Shannon Moore; Melanie H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

4.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

6.  AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

Authors:  Jose V Moyano; Joseph R Evans; Feng Chen; Meiling Lu; Michael E Werner; Fruma Yehiely; Leslie K Diaz; Dmitry Turbin; Gamze Karaca; Elizabeth Wiley; Torsten O Nielsen; Charles M Perou; Vincent L Cryns
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

7.  The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

Authors:  Simone de Leon Martini; Carolina Beatriz Müller; Rosalva Thereza Meurer; Marilda da Cruz Fernandes; Rodrigo Mariano; Mariel Barbachan E Silva; Fábio Klamt; Cristiano Feijó Andrade
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

8.  Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc.

Authors:  W Chen; J L Martindale; N J Holbrook; Y Liu
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.

Authors:  T Fox; J T Coll; X Xie; P J Ford; U A Germann; M D Porter; S Pazhanisamy; M A Fleming; V Galullo; M S Su; K P Wilson
Journal:  Protein Sci       Date:  1998-11       Impact factor: 6.725

10.  Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).

Authors:  Stephen Hiscox; Liam Morgan; Denise Barrow; Carol Dutkowskil; Alan Wakeling; Robert I Nicholson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.